Friday, European stocks ended mixed. The Stoxx Europe 600 Index added 0.16%. Germany's DAX 30 gained 0.35%, the U.K.'s FTSE 100 rose 0.63%, while France's CAC 40 was down 0.31%.
45% of STOXX 600 constituents traded higher Friday.
70% of the shares trade above their 20D MA vs 71% Thursday (above the 20D moving average).
49% of the shares trade above their 200D MA vs 48% Thursday (above the 20D moving average).
The Euro Stoxx 50 Volatility index eased 1.23pt to 25.58, a new 52w high.
SECTORS vs STOXX 600
3mths relative high: Chemicals, Utilities
3mths relative low: Retail, Real Estate
Europe Best 3 sectors
automobiles & parts, basic resources, technology
Europe worst 3 sectors
travel & leisure, insurance, energy
The 10yr Bund yield fell 2bps to -0.47% (below its 20D MA). The 2yr-10yr yield spread rose 0bp to -22bps (above its 20D MA).
GE 07:00: Jun PPI YoY, exp.: -2.2%
GE 07:00: Jun PPI MoM, exp.: -0.4%
EC 09:00: May Current Account, exp.: E10.2B
FR 14:00: 12-Mth BTF auction, exp.: -0.56%
FR 14:00: 3-Mth BTF auction, exp.: -0.56%
FR 14:00: 6-Mth BTF auction, exp.: -0.55%
In Asian trading hours, EUR/USD eased to 1.1419 and GBP/USD slid to 1.2525. USD/JPY rebounded to 107.38. This morning, government data showed that Japan's exports declined 26.2% on year in June (-24.7% expected) and imports slid 14.4% (-17.6% expected).
Spot gold retreated to $1,807 an ounce.
#UK - IRELAND#
GlaxoSmithKline, a pharmaceutical group, said it has signed a strategic collaboration agreement with biotechnology company CureVac for the development and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The company added: "GSK will make an equity investment in CureVac of £130m (E150m), representing close to a 10% stake, an upfront cash payment of £104m (E120m) and a one-time reimbursable payment of £26m (E30m) for manufacturing capacity reservation, upon certification of CureVac's commercial scale manufacturing facility currently under construction in Germany." From a chartist point of view, prices remain stuck within a mid term consolidation channel. The stock price is challenging its 20 and 50 DMAs. The RSI stands above 50% but lacks momentum. Above 1561p, the bias remains bullish. Next resistance thresholds are set at 1749p and 1857p in extension. A break below 1561p would call for a reversal down trend towards 1490p and 1415p.
Source: GAIN Capital, TradingView
Marks & Spencer, a retailing group, will announce hundreds of job cut this week due to the Covid-19, reported Sky News citing people familiar with the matter.
SSE, an energy company, was downgraded to "hold" from "buy" at Societe Generale.
Standard Life Aberdeen, an investment company, was downgraded to "underweight" from "equalweight" at Barclays.
Airbus, an aircraft manufacturer, said it has secured a 500 million pounds contract from the U.K. Ministry of Defence to build an additional satellite to support British military communications until at least 2040.
Natixis', a banking group, owner BPCE said it has no plan to acquire the remaining shares in the company, reported Bloomberg citing an emailed statement.
EssilorLuxottica, an eyewear conglomerate, announced that it has initiated legal proceedings before a Dutch district court to "obtain information from GrandVision. This is to assess the way GrandVision has managed the course of its business during the COVID-19 crisis, as well as the extent to which GrandVision has breached its obligations under the support agreement".
Teleperformance, an omnichannel company, was upgraded to "overweight" from "equalweight" at Morgan Stanley.
Intesa Sanpaolo, an Italian banking group, announced that it has raised is takeover offer for UBI Banca by adding an extra cash portion of 0.57 euro per share, representing about 652 million euros.
Julius Baer, a Swiss private bank, reported that 1H net income rose 43.2% on year to 491 million Swiss franc and operating income grew 8.9% to 1.85 billion Swiss franc. Also, assets under management fell 5.7% to 402 billion Swiss franc.
From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.